DXd-THP achieved a pCR rate of 67.3% versus 56.3% with ddAC-THP, "the highest reported pCR rate in HER2-positive early breast ...

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis ...

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: Daiichi Sankyo Company, in collaboration ...

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class ...

Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to take the middle 5.6-mg/kg dose into the phase 3 part of the trial. The ORR ...

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

Dato-DXd improved outcomes over chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who were ineligible for immunotherapy.

“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...

T-DXd significantly improved IDFS and reduced the risk of invasive disease or death by 53% compared to T-DM1 in high-risk, HER2-positive breast cancer patients. The trial demonstrated superior ...

High School DxD Season 3 was notably the final season produced under TNK, and more notably featured some material that was not from the original light novel releases. High School DxD Hero then finally ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook After a notable break between seasons, the High School DxD anime made its surprising return last ...